Latent Autoimmune Diabetes in Adults: Current Status and New Horizons

다국어 초록 (Multilingual Abstract)

Autoimmune diabetes is a heterogeneous disease which can arise at any age. Subjects with adult-onset autoimmune diabetes who do not necessitate insulin-therapy for at least 6 months after diagnosis are demarcated as having latent autoimmune diabetes in adults (LADA). This condition is more heterogeneous than young-onset autoimmune diabetes and shares clinical and metabolic characteristics with both type 2 and type 1 diabetes. Patients with LADA are considered by having highly variable β-cell destruction, different degrees of insulin resistance and heterogeneous titre and pattern of islet autoantibody, suggesting different pathophysiological pathways partially explaining the heterogeneous phenotypes of LADA. To date the heterogeneity of LADA does not allow to establish a priori treatment algorithm and no specific guidelines for LADA therapy are available. These subjects are mostly treated as affected by type 2 diabetes, a factor that might lead to the progression to insulin-dependency quickly. A personalised medicine approach is necessary to attain optimal metabolic control and preserve β-cell function to decrease the risk of long-term diabetes complications. Recent data concerning the use of oral antidiabetic agents as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists indicate up-and-coming results in term of protect C-peptide levels and improving glycaemic control. This review summarises current knowledge on LADA, emphasising controversies regarding its pathophysiology and clinical features. Moreover, we discuss data available about novel therapeutic approaches that can be considered for prevention of β-cell loss in LADA.

참고문헌 (Reference)

1 Lampasona V, "Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4" 33 : 104-108, 2010

2 Grant SF, "Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes" 38 : 320-323, 2006

3 Turner R, "UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group" 350 : 1288-1293, 1997

4 Buzzetti R, "Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes" 38 : 513-520, 2015

5 D'Alessio DA, "Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes" 94 : 81-88, 2009

6 Petrone A, "The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in Latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3" 31 : 534-538, 2008

7 Roh MO, "The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea" 50 : 129-134, 2013

8 Tuomi T, "The many faces of diabetes: a disease with increasing heterogeneity" 383 : 1084-1094, 2014

9 Rawshani A, "The incidence of diabetes among 0-34 year olds in Sweden: new data and better methods" 57 : 1375-1381, 2014

10 Arikan E, "The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with type 2 diabetes mellitus" 19 : 254-258, 2005

11 Nistico L, "The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry" 5 : 1075-1080, 1996

12 Kobayashi T, "Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM" 45 : 622-626, 1996

13 Napoli N, "Serum sclerostin and bone turnover in latent autoimmune diabetes in adults" 103 : 1921-1928, 2018

14 Buzzetti R, "Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA)" 32 : 289-296, 2016

15 Maddaloni E, "SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes)" 46 : 3-5, 2014

16 Tian L, "Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor" 151 : 3049-3060, 2010

17 Balme M, "Retinopathy in latent autoimmune diabetes of adults: the Fremantle Diabetes Study" 19 : 602-605, 2002

18 Qi X, "Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study" 34 : 66-70, 2011

19 Zinman B, "Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe" 53 : 3193-3200, 2004

20 Hjort R, "Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwegian HUNT Study" 61 : 1333-1343, 2018

21 Maioli M, "Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults" 163 : 541-549, 2010

22 Olsson L, "Mortality in adult-onset autoimmune diabetes is associated with poor glycemic control: results from the HUNT Study" 36 : 3971-3978, 2013

23 Hawa MI, "Metabolic syndrome and autoimmune diabetes: Action LADA 3" 32 : 160-164, 2009

24 Napoli N, "Mechanisms of diabetes mellitus-induced bone fragility" 13 : 208-219, 2017

25 Mollo A, "Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain" 29 : 446-451, 2013

26 Maddaloni E, "Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement" 10 : e0131837-, 2015

27 Andersen MK, "Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years" 33 : 2062-2064, 2010

28 Fourlanos S, "Latent autoimmune diabetes in adults (LADA) should be less latent" 48 : 2206-2212, 2005

29 Naik RG, "Latent autoimmune diabetes in adults (LADA)" 4 : 233-241, 2003

30 Park Y, "LADA prevalence estimation and insulin dependency during follow-up" 27 : 975-979, 2011

31 Hawa MI, "LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes" 37 : 1643-1649, 2014

32 Schloot N, "Isohormonal therapy of endocrine autoimmunity" 16 : 289-294, 1995

33 Barinas-Mitchell E, "Islet cell autoimmunity in a triethnic adult population of the Third National Health and Nutrition Examination Survey" 53 : 1293-1302, 2004

34 Tiittanen M, "Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro" 55 : 3446-3454, 2006

35 Argoud GM, "Insulin suppresses its own secretion in vivo" 36 : 959-962, 1987

36 Hernandez M, "Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes. Action LADA 9" 15 : 1-, 2015

37 Maruyama T, "Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus" 93 : 2115-2121, 2008

38 Haller K, "Insulin gene VNTR, CTLA-4 +49A/G and HLA-DQB1 alleles distinguish latent autoimmune diabetes in adults from type 1 diabetes and from type 2 diabetes group" 69 : 121-127, 2007

39 Bruno G, "Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy" 28 : 2613-2619, 2005

40 Molbak AG, "Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark" 11 : 650-655, 1994

41 Pozzilli P, "Immunomodulation for the prevention of SPIDDM and LADA" 1079 : 90-98, 2006

42 Lee SH, "Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome" 83 : e62-e65, 2009

43 Brooks-Worrell BM, "Identification of autoantibody-negative autoimmune type 2 diabetic patients" 34 : 168-173, 2011

44 Bottazzo GF, "IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)" 48 : 703-708, 2005

45 Buzzetti R, "High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes" 30 : 932-938, 2007

46 Zampetti S, "High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)" 171 : 697-704, 2014

47 Radtke MA, "Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment. Results from the Nord-Trondelag Health (HUNT) study" 32 : 245-250, 2009

48 Maddaloni E, "Getting it right for people with LADA" 59 : 31-32, 2014

49 Bluestone JA, "Genetics, pathogenesis and clinical interventions in type 1 diabetes" 464 : 1293-1300, 2010

50 Sabbah E, "Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes" 23 : 1326-1332, 2000

51 Cervin C, "Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes" 57 : 1433-1437, 2008

52 Howson JM, "Genetic analysis of adult-onset autoimmune diabetes" 60 : 2645-2653, 2011

53 Zampetti S, "GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6)" 97 : 3759-3765, 2012

54 Agardh CD, "GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes" 52 : 1363-1368, 2009

55 Desai M, "GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77" 50 : 2052-2060, 2007

56 Zhou Z, "Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study" 62 : 543-550, 2013

57 Fuchtenbusch M, "Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens" 49 : 918-925, 2000

58 Wang C, "Evaluating peripheral nerve function in asymptomatic patients with type 2 diabetes or latent autoimmune diabetes of adults (LADA): results from nerve conduction studies" 29 : 265-269, 2015

59 Ellis SL, "Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial" 28 : 1176-1181, 2011

60 Jansen A, "Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest?" 9 : 341-348, 1996

61 Pozzilli P, "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials" 20 : 1490-1498, 2018

62 Zhao Y, "Dipeptidyl peptidase 4 inhibitor sitagliptin maintains ${\beta}$-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study" 99 : E876-E880, 2014

63 American Diabetes Association, "Diagnosis and classification of diabetes mellitus" 27 (27): S5-S10, 2004

64 Leslie RD, "Diabetes classification: grey zones, sound and smoke: Action LADA 1" 24 : 511-519, 2008

65 Leslie RD, "Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment" 59 : 13-20, 2016

66 Signore A, "Detection of insulitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10)" 38 : 652-658, 2015

67 Takeda H, "Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study)" 25 : 995-1001, 2002

68 Leslie RD, "Clinical review: type 1 diabetes and latent autoimmune diabetes in adults. One end of the rainbow" 91 : 1654-1659, 2006

69 Genovese S, "Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes" 154 : 441-447, 2006

70 Agardh CD, "Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes" 19 : 238-246, 2005

71 Tuomi T, "Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies" 48 : 150-157, 1999

72 Isomaa B, "Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA)" 22 : 1347-1353, 1999

73 Myhill P, "Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study" 25 : 1245-1250, 2008

74 Yang Z, "Childhood diabetes in China. Enormous variation by place and ethnic group" 21 : 525-529, 1998

75 Van der Auwera BJ, "CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry" 110 : 98-103, 1997

76 Johansen OE, "Beta-cell function in latent autoimmune diabetes in adults treated with linagliptin vs glimepiride: exploratory results from a 2-year double-blind randomized controlled study" 33 (33): 2012

77 Steffes MW, "Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial" 26 : 832-836, 2003

78 Foley JE, "Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial" 54 : 1985-1991, 2011

79 Pozzilli P, "Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention" 24 : 1460-1467, 2001

80 Achenbach P, "Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12" 61 : 1644-1649, 2018

81 Lu J, "Associations between clinical characteristics and chronic complications in latent autoimmune diabetes in adults and type 2 diabetes" 31 : 411-420, 2015

82 Zampetti S, "Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD Study 5)" 27 : 701-704, 2010

83 Tuomi T, "Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease" 42 : 359-362, 1993

84 Barker A, "Age-dependent decline of ${\beta}$-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study" 16 : 262-267, 2014

85 Buzzetti R, "Adult-onset autoimmune diabetes: current knowledge and implications for management" 13 : 674-686, 2017

86 Hawa MI, "Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7" 36 : 908-913, 2013

87 Bottini N, "A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes" 36 : 337-338, 2004

88 Frayling TM, "A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity" 316 : 889-894, 2007